DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $799,186 | -62.8% | 38,739 | -46.8% | 0.00% | -100.0% |
| Q2 2023 | $2,148,328 | -19.5% | 72,800 | -37.1% | 0.00% | 0.0% |
| Q1 2023 | $2,668,147 | +540.9% | 115,805 | +673.6% | 0.00% | – |
| Q4 2022 | $416,288 | +1.5% | 14,969 | +7.5% | 0.00% | – |
| Q2 2022 | $410,000 | -81.2% | 13,923 | -71.6% | 0.00% | – |
| Q4 2021 | $2,184,000 | +131.6% | 48,956 | +161.8% | 0.00% | – |
| Q3 2021 | $943,000 | +179.0% | 18,697 | +333.5% | 0.00% | – |
| Q2 2021 | $338,000 | -54.4% | 4,313 | -66.8% | 0.00% | – |
| Q1 2021 | $741,000 | -78.2% | 12,981 | -67.9% | 0.00% | -100.0% |
| Q4 2020 | $3,393,000 | +217.1% | 40,494 | +35.7% | 0.00% | 0.0% |
| Q3 2020 | $1,070,000 | +93.1% | 29,846 | +30.2% | 0.00% | – |
| Q2 2020 | $554,000 | -18.9% | 22,927 | -41.2% | 0.00% | -100.0% |
| Q1 2020 | $683,000 | +243.2% | 38,966 | +200.3% | 0.00% | – |
| Q3 2019 | $199,000 | -8.7% | 12,976 | +29.5% | 0.00% | – |
| Q3 2018 | $218,000 | – | 10,020 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |